Biotech Values

[DewDiligence]

>Where's the 18 week safety data for ARIES-1?<

In the ARIES-2 PR in December, MYOG reported only the 12-week data, so today’s PR is no different on that score.

>If I was a MYOG holder, that would concern me more than the relatively weak efficacy numbers.<

Why are you interested in the 18-week safety data, specifically? According to today’s PR, MYOG now has a safety database of 400 patients from long-term studies (up from 200 at the time of the ARIES-2 PR).

Which do you think will be the primary dose for the NDA: 5mg, 10mg, or equal billing? Regards, Dew